A pilot study showed that baclofen (GABABR agonist) administration reduced body weight and serum leptin levels in obese patients with no significant changes in blood pressure or metabolism of glucose and lipid, which suggests targeting GABABR might be a novel approach for obesity treatment (116). This evidence concerns the gene LEP and obesity disorder.